SELECTED STATEMENTS OF COMPREHENSIVE LOSS (Tables)

12 Months Ended

Dec. 31, 2016

SELECTED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Schedule of revenue by geographic area

	Year ended December 31, 2016		Year ended December 31, 2015
Licensing Revenue:
Europe	$	1,065	$	869
Total revenue	$	1,065	$	869

Schedule of long-lived assets by geographic area

	December 31,
	2016		2015
Long-lived assets:
Israel	$	375	$	372
United States		330		380
United Kingdom		3,075		1,466
France		61		61
Switzerland		708		304
Total long-lived assets	$	4,549	$	2,583

Schedule of sales to single customer exceeding 10%

	Year ended December 31, 2016			Year ended December 31, 2015
Sales to a single customer exceeding 10%:
Cardiome		100	%		100	%

Schedule of financial expense (income), net

	Year ended December 31,
	2016			2015
Financial expenses:
Interest expense and bank fees	$	97		$	77
Issuance costs allocated to warrants		784			—
	$	881		$	77
Financial income:
Interest income	$	(74	)	$	(50	)
Reevaluation of fair value of warrants to purchase Convertible Preferred Shares		—			(40	)
Reevaluation of fair value of warrants to purchase Ordinary Shares		(2,491	)		—
Foreign currency translation adjustments		(217	)		(75	)
	$	(2,782	)	$	(165	)
Total financial income, net	$	(1,901	)	$	(88	)

Schedule of weighted average number of shares

	Year ended December 31,
	2016		2015
Numerator:
Net loss	$	25,869	$	24,971
Dividends accumulated for the period(*)		—		988
Net loss available to shareholders of Ordinary Shares	$	25,869	$	25,959
Denominator:
Weighted average number of Ordinary Shares used in computing basic and diluted net loss per share		16,253,975		10,593,227

(*)           The net loss used for the computation of basic and diluted net loss per share include the compounded dividend of eight percent per annum which shall be distributed to shareholders in case of distributable assets determined in the AOA under the liquidation preference right.